Yes, Movantik Treats Opioid-Induced Constipation
Movantik (naloxegol) is an FDA-approved oral medication specifically for relieving opioid-induced constipation (OIC) in adults with chronic non-cancer pain.[1] It blocks opioid effects in the gut without reducing pain relief from opioids taken systemically.
How Movantik Works
As a peripherally acting mu-opioid receptor antagonist (PAMORA), Movantik targets opioid receptors in the gastrointestinal tract. This reverses constipation caused by opioids binding to those receptors, while a blood-brain barrier limits central nervous system penetration, preserving analgesia.[1][2]
Who It's Approved For
- Adults with OIC from chronic opioid use for non-cancer pain.
- Not for patients with known or suspected GI obstruction, or those using strong CYP3A4 inhibitors.[1]
First approved by the FDA in 2014 at doses of 12.5 mg or 25 mg once daily.[2]
Common Side Effects Patients Report
Abdominal pain, diarrhea, nausea, flatulence, vomiting, and headache occur most often. Serious risks include GI perforation (especially with risk factors like Crohn's disease) and opioid withdrawal symptoms like hyperhidrosis or chills.[1] Patients on opioids for cancer pain should consider alternatives, as Movantik lacks approval there.
How It Compares to Alternatives
| Drug | Mechanism | Key Differences |
|------|-----------|-----------------|
| Movantik (naloxegol) | PAMORA, oral tablet | Once-daily; doesn't cross blood-brain barrier well. |
| Relistor (methylnaltrexone) | PAMORA, subcutaneous/injectable or oral | Faster onset for acute OIC; approved for cancer pain too. |
| Symproic (naldemedine) | PAMORA, oral | Similar profile; also for non-cancer OIC. |
| Amitiza (lubiprostone) | Chloride channel activator | Non-PAMORA; works via different pathway, no opioid interaction concerns. |
Movantik shows response rates of 40-50% in trials vs. 30% placebo.[2]
When Does the Patent Expire?
Key U.S. patents for Movantik expired in 2023-2024, with some pediatric exclusivity extensions into 2025. Generic challenges are ongoing; check DrugPatentWatch.com for latest litigation and entry dates.[3]
[1] Movantik Prescribing Information, FDA (via DailyMed).
[2] Clinical Pharmacology Review, FDA Approval Package.
[3] DrugPatentWatch.com (search "naloxegol").